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Abstract
Objective The aim of this study was to evaluate the po-
tential of 18F-fluorodeoxyglucose-positron emission to-
mography (18F-FDG-PET) for monitoring the therapeutic
efficacy of TAK-733, an inhibitor of mitogen-activated
protein kinase kinase, in nude rats bearing A549 (human
lung carcinoma) xenografts.
Methods TAK-733 was administered orally by gavage to
nude xenograft rats for 2 weeks, at dosage levels of 0
(0.5 % w/v methylcellulose solution), 1, 3, and 10 mg/
kg/day (n = 8/dose). Tumor size was measured before
treatment (day 0), and on days 1, 3, 7, 9, 11, and 14. PET
scans were performed pretreatment (day 0), and on days 2,
4, 7, 10, and 14. Tracer accumulations in tumor tissue were
quantified as the mean standard uptake value (SUVmean).
Results No deaths or treatment-related body weight
losses occurred during the study period. TAK-733 showed
dose-dependent inhibition of tumor growth and 18F-FDG
uptake in tumor tissue. At a dosage of 10 mg/kg, TAK-
733 treatment produced a statistically significant reduction
in tumor weight from day 11 compared with the vehicle
group (P\ 0.05). Tumor growth was inhibited in the
10 mg/kg group with a treated/control value of 31 % on
day 14. The SUVmean on day 2 in this dosage group was
statistically lower than that observed on day 0, and that
seen in the vehicle group on day 2 (P\ 0.05 for both
comparisons). Furthermore, this reduction in SUVmean at
10 mg/kg was maintained over time. In the two lower
dosage groups (1 and 3 mg/kg), SUVmean gradually in-
creased over time.
Conclusions 18F-FDG-PET enabled early determination
of late anti-tumor activity in response to TAK-733
treatment.
Keywords TAK-733  18F-FDG-PET  MEK inhibitor 
A549 xenograft rat
Introduction
Mitogen-activated protein kinase kinases 1 and 2 (MEK1/
2) are tyrosine and serine/threonine dual-specific kinases,
included in the mitogen-activated protein kinase (MAPK)
cascade, which play an essential role in cell proliferation,
cell cycle regulation, survival, and migration [1, 2]. Inap-
propriate MAPK pathway activation is observed in C50 %
of human cancers, including colon, lung, breast, pancreas,
melanoma, ovary, and kidney cancer [3]. TAK-733 is a
novel, potent, selective, non-adenosine triphosphate
(ATP)-competitive, allosteric inhibitor of MEK1/2 kinase,
which has the potential to inhibit cancer proliferation [4].
Positron emission tomography (PET) is widely used in
clinical cancer diagnosis and is increasingly being used to
& Ikuo Mori
ikuo.mori@takeda.com
1 Integrated Technology Research Laboratories,
Pharmaceutical Research Division, Takeda Pharmaceutical
Company Limited, 26-1, Muraoka-Higashi 2 chome,
Fujisawa, Kanagawa 251-8555, Japan
2 Drug Discovery Unit, Pharmaceutical Research Division,
Takeda Pharmaceutical Company Limited, Fujisawa,
Kanagawa 251-8555, Japan
3 Discovery Biology, Takeda San Diego, San Diego, CA 9212,
USA
4 Present Address: Research and Development Consulting,
Encinitas, CA 92024, USA
5 Former Employee of Takeda San Diego, San Diego,
CA 9212, USA
123
Ann Nucl Med (2015) 29:613–620
DOI 10.1007/s12149-015-0984-4
assess the response to anti-cancer therapy. 18F-
fluorodeoxyglucose (18F-FDG) is a glucose analog that is
taken up into tumor cells by glucose transporters. Within
cells, it is phosphorylated by hexokinase to 18F-FDG
phosphate, which becomes trapped inside the cells; unlike
glucose 6-phosphate, 18F-FDG phosphate is not a substrate
for further glycolytic metabolism, and its level of de-
phosphorylation to 18F-FDG is low [5]. Most tumors ex-
press large numbers of glucose transporters together with
high hexokinase activity, and therefore exhibit high 18F-
FDG uptake; so the primary clinical application of PET
uses 18F-FDG as a biomarker to detect changes in glucose
metabolism. Effective therapies that kill tumor cells and/or
target cell glucose metabolism would be expected to reduce
local glucose utilization relative to pretreatment values,
although certain therapies can cause transient increases in
glucose metabolism too.
18F-FDG-PET imaging has proved itself a valuable
tool in the successful clinical development of several
oncology drugs, for example Pfizer’s sunitinib for the
treatment of gastrointestinal stromal tumors and ad-
vanced kidney cancer, and Novartis’s imatinib for the
treatment of gastrointestinal stromal tumors [6, 7]. In
clinical studies of these agents, 18F-FDG-PET imaging
has revealed significant metabolic reduction in tumor
tissue prior to tumor burden reduction and/or clinical
benefit. This ability to detect an early indication of drug
efficacy has provided confidence for the further devel-
opment of these drugs, especially with regard to con-
tinued investment decisions.
Prior to many clinical studies, in vivo preclinical
studies are often performed to characterize the drug of
interest. Drug activity in animal studies is commonly
determined by measuring post-treatment changes in the
size of tumors that have been implanted subcutaneously.
However, the accuracy of the measurement is affected
by the thickness of the subcutaneous fat layer, as well as
by hair and fur. Recently, 18F-FDG-PET has been used
with high-resolution, small animal scanning equipment,
as an adjunct to traditional measures of anti-tumor ac-
tivity, to evaluate metabolic responses in these xenograft
models [6].
This study examined the efficacy of TAK-733 against
A549 human, non-small cell lung carcinoma (NSCLC)
xenografts in nude rats. 18F-FDG-PET assessment of
therapeutic efficacy was compared with tumor growth in-
hibition [treated/control (T/C)], measured by conventional
caliper assessment of tumor size. The broad aims of the
study were to evaluate: (1) whether 18F-FDG uptake can be
used as an early indicator of tumor growth inhibition by






idine-4,7(3H,8H)-dione (Takeda California, CA, USA) was
prepared in 0.5 % w/v methylcellulose 400 (Wako Che-
mical USA, Richmond, VA, USA) (Fig. 1) [4].
Animals and husbandry
All studies were conducted at Molecular Imaging, Inc.,
Ann Arbor, MI, USA. The rats were housed and main-
tained in accordance with Institutional Animal Care and
Use Committee (IACUC), state, and federal guidelines.
The 32 animals were 7–9 weeks old at the time of tumor
implantation, and were fed irradiated Rodent Diet 5053
(LabDietTM) and water ad libitum. They were housed in
static cages with Bed-O’CobsTM bedding inside Biobub-
ble Clean Rooms that provided HEPA-filtered air into the
bubble environment at 100 complete air changes per hour.
All treatments and body weight determinations were car-
ried out in the bubble environment. The temperature was
maintained at 22 ± 2 C with a humidity range of
30–70 %.
Test animals were implanted subcutaneously to the right
flank with 30–60 mg tumor fragments of A549 human,
non-small cell lung carcinoma (NSCLC) using a 10-gauge
trocar needle. All animals were observed for clinical signs
at least once daily. Animals with tumors in excess of 5 g,
or with ulcerated tumors, were euthanized, as were those
found in obvious distress or in a moribund condition.
Treatment
Treatment began when the mean estimated tumor weight
for all groups (vehicle, 1, 3, 10 mg/kg, n = 8/group) was
250 mg (range of group means 214–297 mg). All animals
Fig. 1 Chemical structure of TAK-733
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weighed C145 g at the initiation of therapy. Mean group
body weights at first treatment were well matched (range of
group means 167–190 g). All animals were dosed accord-
ing to individual body weight on the day of treatment
(10 mL/kg) as indicated in the protocol.
PET imaging
PET was performed using a Siemens R4 small animal
lPET scanner and 18F-FDG radiotracer (IBA Molecular).
Pretreatment PET scans were acquired on day 0. Post-
treatment imaging occurred on days 2, 4, 7, 10, and 14. The
animals were fasted for at least 6 h before the start of
imaging to minimize blood glucose levels. They were
subsequently anesthetized with 1.75 % isoflurane in air and
injected in the tail vein with approximately 400 lCi of 18F-
FDG. 18F-FDG uptake occurred under anesthesia for 1.5 h.
Body temperature was maintained with a thermostat-
regulated, re-circulating water-heated pad and measured as
rectal temperature. Individual body weights were recorded
before each imaging session. Static emission data were
acquired for 13 min using a single bed position.
PET image analysis and endpoints
The PET list mode data were converted to 2-dimensional
(2D) sinograms, corrected for random coincidences, and
normalized for scanner uniformity. Attenuation-corrected
PET images were reconstructed using an iterative 2D,
ordered subsets expectation maximization (OSEM) algo-
rithm. The entire tumor was segmented in the PET images
using the Amira Segmentation Editor. Tumor regions of
interest (ROIs) were drawn in three orthogonal planes by a
well-trained technician according to caliper-based tumor
length and width, and an ellipsoidal tumor volume was
then interpolated by the software. Software-calculated tu-
mor volumes were compared against caliper-based vol-
umes to ensure consistency (average difference 1.08 %).
The mean PET tumor signal was calculated from all voxels
within the ROIs and converted to 18F activity units. The
mean 18F-FDG standardized uptake value (SUVmean) was
calculated according to the relation:
SUVmean ¼ mean radioactivity in the tumor ðlCi=gÞ
 body weight gð Þ=injected dose
 decay  correctedð Þ ðlCiÞ:
Measurements and endpoints
Testing was carried out by adhering to the general princi-
ples established by the groups of Schabel, Skipper, Gris-
wold, Corbett, Leopold, Ross, and the National Cancer
Institute (NCI) [8–11]. Body weights and tumor size were
measured before treatment (day 0), and on days 1, 3, 7, 9,
11, and 14. Tumor weight (mg) was estimated from caliper
measurements using the formula for the volume of a pro-
late ellipsoid assuming unit density:
Tumor weight mgð Þ ¼ LW2 =2;
where L and W are the respective orthogonal tumor length
and width measurements (mm).
The primary endpoint used to evaluate efficacy was %T/
C, which was defined as the ratio of median tumor weight
in the treated versus control (vehicle) group 9 100. In this
experiment, %T/C was evaluated on each day. The NCI
standard for significant anti-tumor activity in xenograft
models is T/C B 41 % [12–15]. All animals were observed
for clinical signs at least once daily.
Histology
After the last PET measurement, animals were killed and
subcutaneous tumors were extracted. Formalin-fixed (10 %),
paraffin-embedded sections (4 lm) of resected specimens
from tumor tissue were taken for staining. Hematoxylin and
eosin (H&E) staining was conducted according to standard
protocols. Ki-67 immunohistochemical staining was per-
formed using the labeled streptavidin biotinylated antibody
(LSAB) method with an autostaining system (Ventana
Medical Systems Inc., USA) according to the manufacturer’s
protocol. MIB-1 antibody (DAKO), a monoclonal murine
antibody specific for human nuclear antigen Ki-67, was used
as the primary antibody in a 1:100 dilution.
The Ki-67 index (%) was estimated by counting the
percentage of Ki-67-positive cell nuclei per 200–300 tumor
cells in the region of the tumor with the greatest density of
staining, which in most instances corresponded to areas
with the highest mitotic activity, as determined by H&E
staining.
Statistics
Differences in tumor volumes between pairs of treatment
groups were assessed on days 0, 1, 3, 7, 9, 11, and 14.
Estimated tumor weights were compared by applying a
pairwise Wilcoxon rank-sum test, with P value (P\ 0.05)
adjustment by the method of Holm (non-parametric test).
The same statistical methodology was used in the ana-
lysis of the 18F-FDG-PET data to: (1) compare normalized
18F-FDG SUVmean between groups at each imaging time
point; and (2) compare normalized SUVmean between
imaging time points for each group.
The Ki-67 index was analyzed statistically using the
Shirley–Williams test at a two-tailed significance level of
Ann Nucl Med (2015) 29:613–620 615
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0.025, assuming a dose-related trend was performed. The
Shirley–Williams test was performed using the SAS
function PROBMC.
Results
Anti-tumor effects of TAK-733
TAK-733 was tolerated, and did not result in mean body
weight loss at any dosage level (Fig. 2). There were no
treatment-related deaths in any of the animals that received
TAK-733 either.
TAK-733 treatment resulted in dose-dependent tumor
growth inhibition. TAK-733 at a dosage level of 10 mg/kg
produced a statistically significant reduction in estimated
tumor weight compared with vehicle administration on day
11 (mean ? standard deviation, 314 ? 161 vs.
817 ? 375 mg, respectively; P\ 0.05) (Fig. 3).
When dosed at 10 mg/kg, TAK-733 produced a mini-
mum T/C value of 31 % on day 14, which is indicative of
clinically significant anti-tumor activity based on the NCI
definition (B41 %) (Table 1). At 1 and 3 mg/kg, TAK-733
did not produce clinically significant T/C values on day 14
(55 and 44.0 %, respectively). There were no marked dif-
ferences in T/C values among the three TAK-733 dosage
groups during the early treatment phase (days 1 and 3), but
there was a trend for dose dependency of T/C values during
the later treatment phase (days 7, 9, 11, and 14) (Table 1).
H&E staining images revealed tumor cell necrosis in the
10 mg/kg group (Fig. 4a). Staining showed pyknotic nuclei
and eosinophilic cytoplasm in multifocal lesions. Ki-67-
positive cells were frequently detected in the tumor tissue
from the vehicle group; however, Ki-67 nuclear staining was
barely detectable in the TAK-733 10 mg/kg dosage group
(Fig. 4a). A statistically significant decrease in the Ki-67
index was observed in the 1, 3, and 10 mg/kg dosage groups
(P\ 0.025 vs. vehicle for all comparisons) (Fig. 4b).
PET study
18F-FDG-PET images showed clear uptake of the tracer in
tumor tissue, compared with background tissue in most
cases. Relatively homogenous tumor uptake was seen
throughout the study with only a few exceptions, where
heterogeneous uptake was observed (Fig. 5).
18F-FDG SUVmean gradually increased over time, and
to a similar extent, in the vehicle and TAK-733 1 mg/kg
groups (Fig. 6). A slight reduction in SUVmean was ob-
served in the 3 mg/kg dosage group on day 2, but this
change was not statistically significant (not significant
change between: vehicle and 3 mg/kg dosage group and
between pretreatment and mg/kg dosage group) and values
increased gradually over time thereafter. In contrast, a
13.2 % reduction in SUVmean compared with pretreat-
ment was observed in the 10 mg/kg group on day 2
(P\ 0.05), which persisted throughout the study. The
percentage reduction in SUVmean from day 0 at 10 mg/kg
on day 2 was significantly different to that seen in the
vehicle and 1 mg/kg groups (mean ? standard deviation,
87 ? 8 vs. 101 ? 2 % and 105 ? 8 %, respectively;
P\ 0.05 for both comparisons). On day 14, the absolute
SUVmean at 10 mg/kg was significantly lower than that
reported for the vehicle group (1.5 ? 0.3 vs. 2.2 ? 0.3,
respectively; P\ 0.05). Further, the percentage change in
SUVmean at 10 mg/kg on day 14 was significantly dif-
ferent to that observed at 1 mg/kg (91 ? 14 vs.
136 ? 7 %, respectively; P\ 0.05) (Fig. 6).
Fig. 2 Effects of TAK-733 on the body weight of A549 tumor-
bearing rats. A549 tumor-bearing rats were orally administered TAK-
733 (1, 3, 10 mg/kg) or vehicle once daily for 2 weeks. Data are
shown as mean ? standard deviation (SD) (n = 8/group). Black,
blue, green and red lines and markers indicate the vehicle, and TAK-
733 1, 3, and 10 mg/kg dosage groups, respectively. Left body weight
(g), right percentage change in body weight from day 0
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Discussion
This preclinical study examined the correlation between
early 18F-FDG-PET changes and changes in tumor size.
The specific aims of the study were to evaluate whether
TAK-733 treatment in rats bearing A549 human NSCLC
xenografts resulted in an 18F-FDG-PET change, and whe-
ther the PET response change occurred earlier than mor-
phological changes. Using this xenograft model of human
lung carcinoma, we show that the anti-tumor effects of
TAK-733 can be detected by 18F-FDG-PET.
In the TAK-733 10 mg/kg dosage group, the percentage
change in 18F-FDG SUVmean on day 2 was statistically
lower than that observed at pretreatment (P\ 0.05), and
statistically lower than the SUVmean in the vehicle and
1 mg/kg groups (both P\ 0.05). In contrast, the SUVmean
in the vehicle group, and TAK-733 1 and 3 mg/kg groups
actually increased over time. On day 14, the SUVmean at
10 mg/kg (absolute value and percentage change from day
0) was significantly lower than that in the vehicle group
(P\ 0.05). TAK-733 is a novel allosteric inhibitor of
MEK1/2, which not only impairs cell proliferation, but also
impacts a diverse array of cellular events, including dif-
ferentiation, apoptosis, and angiogenesis [1–4]. While 18F-
FDG-PET can be used to detect tissues with abnormal
glucose metabolism that may change in response to therapy,
it is not yet clear whether TAK-733 itself directly affects
glucose metabolic activity. A direct effect of a similar MEK
inhibitor drug on glucose metabolism has been reported
recently [15]; however, impairing cell proliferation and
other cellular events will also alter glucose consumption
levels in cancer cells. In the present study, the anti-prolif-
erative effect was shown as Ki-67 index suppression on day
14 especially in the 10 mg/kg group with low 18F-FDG
uptake, which indicates that the glucose consumption was
inhibited via an anti-proliferative effect of TAK-733.
Compared with vehicle administration, treatment with
TAK-733 10 mg/kg resulted in a statistically significant
reduction in tumor weight on day 11, and a statistically
significant decrease in the percentage change in 18F-FDG
SUVmean from baseline on day 2. This statistical differ-
ence between the 10 mg/kg and vehicle groups did not
persist, however, and was only observed at these single
timepoints for both of these endpoints. As the PET re-
sponse change (SUVmean, day 2) was observed earlier
than the morphological changes (day 11), 18F-FDG-PET
may have the potential to detect early responses to TAK-
733 in lung carcinoma. Given the transient reduction in
SUVmean at 3 mg/kg, it would be interesting to repeat
these experiments using intermediate doses of TAK-733 (5
and 7 mg/kg) to fully evaluate the effect of treatment on
18F-FDG uptake.
Fig. 3 Effects of TAK-733 on the growth of human lung carcinoma
A549 tumors in a xenograft rat model. Oral once-daily administration
of TAK-733 (1, 3, 10 mg/kg) or vehicle was initiated when tumors
reached a weight of 224–297 mg in A549 tumor-bearing rats. Data
are expressed as mean ? standard deviation (SD) (n = 8/group).
Black, blue, green and red lines and markers indicate the vehicle, and
TAK-733 1, 3, and 10 mg/kg dosage groups, respectively. Left A549
tumor weight (mg), right percentage change in tumor weight from day
0. *1: P\ 0.05 vs. vehicle (Wilcoxon rank-sum test)
Table 1 Mean %T/C values for median tumor weight by dosage
group and day of study in A549 tumor-bearing rats receiving once-
daily oral administration of TAK-733 (1, 3, 10 mg/kg) or vehicle for
2 weeks (n = 8/group)
TAK-733 dosage group %T/C values by day of study
0 1 3 7 9 11 14
Vehicle 100 100 100 100 100 100 100
1 mg/kg 76 82 71 78 68 60 55
3 mg/kg 93 102 70 68 53 42 44
10 mg/kg 84 83 62 47 37* 36* 31*
%T/C ratio of median tumor weight in the treated versus control
(vehicle) group 9 100
*%T/C value B41 % (National Cancer Institute threshold for sig-
nificant anti-cancer activity)
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As well as a marker of glucose metabolism, 18F-FDG
uptake in tumors is also a marker of overall tumor energy
consumption, which relates to the number of viable tumor
cells [17, 18]. Reduction of glucose metabolism could
represent a central indicator of overall anti-tumor activity,
with various mechanisms leading to tumor cell death [19,
20]. These effects imaged by 18F-FDG-PET have been used
as a pharmacodynamic marker of anti-tumor activity for a
broad spectrum of anti-cancer therapies in clinical settings
[16, 21–23]. Furthermore, recent studies in tumor models
demonstrate that the reduction in 18F-FDG uptake also
reflects the anti-proliferative effects of drug therapies and
treatment-induced tumor apoptosis [24, 25]. In the present
study, a dose-dependent 18F-FDG uptake regression was
observed along with tumor size reduction (Figs. 3, 6) and
anti-proliferative effect of TAK-733 was confirmed in the
Ki-67 staining (Fig. 4). Therefore, we concluded that this
18F-FDG uptake regression can be used to predict tumor
growth inhibition via the anti-proliferative effect of TAK-
733. The PET tracer, 18F-FLT (30-deoxy-30-18F-fluor-
othymidine), can be used to detect cell proliferation. In
consideration with the MEK inhibition pathway of TAK-
733, Leyton et al. reported that 18F-FLT-PET is a sensitive
imaging biomarker for detecting the anti-proliferative ef-
fect of MEK1/2 inhibition by PD0325901 (MEK inhibitor)
[26]. However, as 18F-FDG-PET is widely used for cancer
diagnosis, staging and treatment response, and is feasible
for use in the clinical setting in comparison with 18F-FLT-
PET, 18F-FDG-PET was selected as the preferred transla-
tional imaging modality for this study.
Fig. 4 Anti-proliferative effects of TAK-733 in tumor tissue. a Rep-
resentative images showing H&E staining and Ki-67 immunohisto-
chemical staining in the vehicle and TAK-733 10 mg/kg dosage
groups. Magnification is 945. b Mean Ki-67 index in each dosage
group (%). Data are expressed as mean ? standard deviation (SD)
(n = 8/group). *P\ 0.025 vs. vehicle (Shirley–Williams test)
Fig. 5 Representative 18F-FDG-PET images on day 14 following
oral administration of TAK-733 (1, 3, 10 mg/kg) or vehicle once
daily for 2 weeks in A549 tumor-bearing rats. The purple line border
of implanted tumor ROI, the volume of which was consistent with
caliper-based volume (average differences 1.08 %). L liver, K kidney
618 Ann Nucl Med (2015) 29:613–620
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Conclusion
Early response to anti-proliferative treatment in A549 lung
carcinoma can be visualized with 18F-FDG-PET, and those
changes in tracer accumulation after the treatment correlate
with TAK-733 efficacy. Thus, 18F-FDG-PET has the po-
tential to detect early responses to TAK-733 in lung
carcinoma.
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